DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Krishna Institute of Medical Sciences Limited — Agreements

NSE 1 hr ago·29 Oct 2026, 5:35 pm

Krishna Inst OF MED SCI L

Krishna Institute of Medical Sciences Limited (KIMS) has informed stock exchanges regarding the execution of various agreements. The company has disclosed that it has entered into new business arrangements, though specific details regarding the nature and value of these deals were not provided in the initial notification.

For investors, this development signals that the hospital group is actively pursuing strategic growth and expansion opportunities. Such agreements often indicate potential new service lines, partnerships, or infrastructure developments that could influence the company's future operational scope and financial performance.

Investors should monitor the official exchange filings for further details on the specific agreements. Keeping an eye on how these new ventures integrate into KIMS's existing operations will be key to understanding their long-term impact on the stock.